Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S2W-04374 · Session 2

Further to the answer to question S2W-3840 by Malcolm Chisholm on 18 November 2003, why the Medicines and Healthcare Products Regulatory Ag…

Answered Asked by Adam Ingram SNP Lodged 24 Nov 2003

The question

To ask the Scottish Executive, further to the answer to question S2W-3840 by Malcolm Chisholm on 18 November 2003, why the Medicines and Healthcare Products Regulatory Agency is working with vaccine manufacturers to make every effort to remove or reduce the thiomersal component in vaccines and what advice the agency has issued to the Minister for Health and Community Care regarding its actions.

The answer

Answered by Malcolm Chisholm on 8 Dec 2003 · 14 days after it was lodged, on time

There is strong evidence tosuggest that thiomersal in vaccines does not cause any harm (except for skinrashes or local swelling at the site of injection). Despite this, and as partof a global goal to reduce exposure to mercury from avoidable sources ingeneral, the European Agency for the Evaluation of Medicinal Products (EMEA)has recommended that vaccine manufacturers phase out use of thiomersal whereverpossible as a purely precautionary measure. The Committee on Safety ofMedicines endorses this recommendation. As the body responsible for the safetyof all medicines available on the UK market, the medicines and health care products regulatoryagency is working with vaccine manufacturers to implement the EMEArecommendations.

In the Official Report

No contribution in the Official Report cites S2W-04374 by reference.